Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
15 hedge funds and large institutions have $14.7M invested in Peak Bio, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
26.39% more ownership
Funds ownership: 0% → 26.39% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.94M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$1.57M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$1.46M |
| 4 |
SCM
Saba Capital Management
New York
|
+$1.45M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.39M |
Top Sellers
PKBO Hedge Fund Activity: Q1 2021 in Review
15 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q1 2021, worth a combined $14.7M.
Buyers outnumbered sellers: 15 funds opened new PKBO positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $1.94M.
- 15 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $14.7M of Peak Bio, Inc. Common Stock stock for Q1 2021.
- 15 funds opened new Peak Bio, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +15 holders.
- The largest Peak Bio, Inc. Common Stock buyer in Q1 2021 was Hudson Bay Capital Management, an estimated $1.94M added.
Based on aggregated 13F filings for Q1 2021.